驱动蛋白家族成员C1在三阴性乳腺癌中的作用机制

Mechanism of driver protein family member C1 in triple negative breast cancer

目的探究驱动蛋白家族成员C1(KIFC1)在三阴性乳腺癌(TNBC)中的功能和作用。方法通过生物信息学的方法分析KIFC1在TNBC组织及癌旁正常组织中的mRNA水平,并分析其表达与患者的生存率间的关系。回顾性分析96例TNBC患者的临床病理特征资料。用免疫组织化学的方法检测肿瘤组织和癌旁正常组织中KIFC1的表达,分析TNBC患者的KIFC1表达及与临床病理特征的关系。结果生物信息学分析结果显示,TNBC组织中KIFC1高表达且与患者的无病生存期相关(P<0.05)。在TNBC组织中,KIF23阳性高表达率为58.3%,而在癌旁组织中主要是低表达或无表达。KIF23的高表达与TNBC患者的肿瘤分级相关(P<0.05)。体外细胞实验结果表明,敲低KIFC1可显著降低TNBC细胞的集落形成能力和增殖能力。小鼠体内实验结果表明,敲低KIFC1可显著降低肿瘤体积。结论KIFC1可作为TNBC的预后因子,低表达KIFC1可在体内外抑制TNBC细胞的增殖。KIFC1有望作为TNBC的预后标志物和治疗靶点。

Objective To explore the function and role of kinesin family member C1(KIFC1)in triple negative breast cancer(TNBC).Methods The mRNA level of KIFC1 in TNBC tissues and normal tissues adjacent to cancer was analyzed by bioinformatics methods,and the relationship between its expression and the survival rate of thepatients was analyzed.The clinicopathological characteristics of 96 TNBC patients were retrospectively analyzed.Immunohistochemical method was used to detect the expression of KIFC1 in tumor tissues and normal tissues adjacent to cancer,and to analyze the expression of KIFC1 in TNBC patients and its relationship with clinicopathological characteristics.Results The results of bioinformatics analysis showed that KIFC1 is highly expressed in TNBC tissue and is correlated with the patient's disease-free survival(P<0.05).In TNBC tissue,the positive high expression rate of KIF23 is 58.3%,while it is mainly low or no expressionin adjacent tissues.The high expression of KIF23 is related to the tumor grade of TNBC patients(P<0.05).The results of in vitro cell experiments show that knocking down KIFC1 can significantly reduce the colony forming ability and proliferation ability of TNBC cells.The results of in vivo experiments in mice showed that knocking down KIFC1 can significantly reduce tumor volume.Conclusions KIFC1 can be used as a prognostic factor of TNBC.Low expression of KIFC1 can inhibit the proliferation of TNBC cells in vivo and in vitro.KIFC1 is expected to be a prognostic marker and therapeutic target for TNBC.